141 related articles for article (PubMed ID: 24533556)
1. Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab.
Shima Y; Hosen N; Hirano T; Arimitsu J; Nishida S; Hagihara K; Narazaki M; Ogata A; Tanaka T; Kishimoto T; Kumanogoh A
Mod Rheumatol; 2015 Jan; 25(1):134-7. PubMed ID: 24533556
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of patients with systemic sclerosis treated with tocilizumab: Case series and review of the literature.
Zacay G; Levy Y
Best Pract Res Clin Rheumatol; 2018 Aug; 32(4):563-571. PubMed ID: 31174825
[TBL] [Abstract][Full Text] [Related]
3. Add-on tocilizumab versus conventional treatment for systemic sclerosis, and cytokine analysis to identify an endotype to tocilizumab therapy.
Shima Y; Kawaguchi Y; Kuwana M
Mod Rheumatol; 2019 Jan; 29(1):134-139. PubMed ID: 29529897
[TBL] [Abstract][Full Text] [Related]
4. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.
Shima Y; Kuwahara Y; Murota H; Kitaba S; Kawai M; Hirano T; Arimitsu J; Narazaki M; Hagihara K; Ogata A; Katayama I; Kawase I; Kishimoto T; Tanaka T
Rheumatology (Oxford); 2010 Dec; 49(12):2408-12. PubMed ID: 20819796
[TBL] [Abstract][Full Text] [Related]
5. Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis.
Arnold MB; Khanna D; Denton CP; van Laar JM; Frech TM; Anderson ME; Baron M; Chung L; Fierlbeck G; Lakshminarayanan S; Allanore Y; Riemekasten G; Steen V; Müller-Ladner U; Spotswood H; Burke L; Siegel J; Jahreis A; Furst DE; Pope JE
Rheumatology (Oxford); 2018 Jan; 57(1):152-157. PubMed ID: 29077900
[TBL] [Abstract][Full Text] [Related]
6. Tocilizumab therapy in juvenile systemic sclerosis: a retrospective single centre pilot study.
Adrovic A; Yildiz M; Haslak F; Koker O; Aliyeva A; Sahin S; Barut K; Kasapcopur O
Rheumatol Int; 2021 Jan; 41(1):121-128. PubMed ID: 33108799
[TBL] [Abstract][Full Text] [Related]
7. Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study.
Nacci F; Righi A; Conforti ML; Miniati I; Fiori G; Martinovic D; Melchiorre D; Sapir T; Blank M; Shoenfeld Y; Pignone AM; Cerinic MM
Ann Rheum Dis; 2007 Jul; 66(7):977-9. PubMed ID: 17344244
[TBL] [Abstract][Full Text] [Related]
8. Anti-interleukin 6 Therapy Effect for Refractory Joint and Skin Involvement in Systemic Sclerosis: A Real-world, Single-center Experience.
Panopoulos ST; Tektonidou MG; Bournia VK; Arida A; Sfikakis PP
J Rheumatol; 2022 Jan; 49(1):68-73. PubMed ID: 34393104
[TBL] [Abstract][Full Text] [Related]
9. Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors.
Tanaka Y; Takeuchi T; Amano K; Saito K; Hanami K; Nawata M; Fukuyo S; Kameda H; Kaneko Y; Kurasawa T; Nagasawa H; Hoshi D; Sato E; Yamanaka H
Mod Rheumatol; 2014 May; 24(3):399-404. PubMed ID: 24252045
[TBL] [Abstract][Full Text] [Related]
10. Discrepancy between clinical and radiological responses to tocilizumab treatment in patients with systemic-onset juvenile idiopathic arthritis.
Aoki C; Inaba Y; Choe H; Kaneko U; Hara R; Miyamae T; Imagawa T; Mori M; Oba MS; Yokota S; Saito T
J Rheumatol; 2014 Jun; 41(6):1171-7. PubMed ID: 24786929
[TBL] [Abstract][Full Text] [Related]
11. A three-year follow-up study of the development of joint contractures in 131 patients with systemic sclerosis.
Bálint Z; Farkas H; Farkas N; Minier T; Kumánovics G; Horváth K; Solyom AI; Czirják L; Varjú C
Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-68-74. PubMed ID: 25152080
[TBL] [Abstract][Full Text] [Related]
12. Critical contribution of the interleukin-6/signal transducer and activator of transcription 3 axis to vasculopathy associated with systemic sclerosis.
Taniguchi T; Asano Y; Fukasawa T; Yoshizaki A; Sato S
J Dermatol; 2017 Aug; 44(8):967-971. PubMed ID: 28342234
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study.
Elhai M; Meunier M; Matucci-Cerinic M; Maurer B; Riemekasten G; Leturcq T; Pellerito R; Von Mühlen CA; Vacca A; Airo P; Bartoli F; Fiori G; Bokarewa M; Riccieri V; Becker M; Avouac J; Müller-Ladner U; Distler O; Allanore Y;
Ann Rheum Dis; 2013 Jul; 72(7):1217-20. PubMed ID: 23253926
[TBL] [Abstract][Full Text] [Related]
14. Mandibular function is severely impaired in systemic sclerosis patients.
Ferreira EL; Christmann RB; Borba EF; Borges CT; Siqueira JT; Bonfa E
J Orofac Pain; 2010; 24(2):197-202. PubMed ID: 20401358
[TBL] [Abstract][Full Text] [Related]
15. Development of a modified hand mobility in scleroderma (HAMIS) test and its potential as an outcome measure in systemic sclerosis.
Sandqvist G; Nilsson JÅ; Wuttge DM; Hesselstrand R
J Rheumatol; 2014 Nov; 41(11):2186-92. PubMed ID: 25274889
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of self-administered stretching for finger joint motion in Japanese patients with systemic sclerosis.
Mugii N; Hasegawa M; Matsushita T; Kondo M; Orito H; Yanaba K; Komura K; Hayakawa I; Hamaguchi Y; Ikuta M; Tachino K; Fujimoto M; Takehara K; Sato S
J Rheumatol; 2006 Aug; 33(8):1586-92. PubMed ID: 16881115
[TBL] [Abstract][Full Text] [Related]
17. Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis.
Sakkas LI
Drug Des Devel Ther; 2016; 10():2723-8. PubMed ID: 27621593
[TBL] [Abstract][Full Text] [Related]
18. Effects of the myofascial release in diffuse systemic sclerosis.
Martin MM
J Bodyw Mov Ther; 2009 Oct; 13(4):320-7. PubMed ID: 19761954
[TBL] [Abstract][Full Text] [Related]
19. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.
DeMarco PJ; Weisman MH; Seibold JR; Furst DE; Wong WK; Hurwitz EL; Mayes M; White B; Wigley F; Barr W; Moreland L; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Clements PJ
Arthritis Rheum; 2002 Nov; 46(11):2983-9. PubMed ID: 12428241
[TBL] [Abstract][Full Text] [Related]
20. Clinical worsening following discontinuation of tocilizumab in diffuse cutaneous systemic sclerosis: a single-centre experience in Japan.
Isomura Y; Shirai Y; Kuwana M
Rheumatology (Oxford); 2022 Nov; 61(11):4491-4496. PubMed ID: 35258561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
